title: Effects of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies.
abstract: OBJECTIVE
  To evaluate the safety of dermal application of 10.0% imidacloprid-0.08% ivermectin in ivermectin-sensitive Collies at dose rates of 3 to 5 times the proposed maximum therapeutic dose.
  
  
  METHODS
  15 Collies (5 males and 10 females) that were confirmed as ivermectin-sensitive dogs.
  
  
  METHODS
  Dogs were assigned to 3 treatment groups (control, 3X, or 5X group) in a randomized block design on the basis of the maximal ivermectin-sensitivity score obtained during preliminary screening. Dogs in groups 3X and 5X were treated at 3 and 5 times the maximum label dose, respectively. Control dogs received an application of an equal volume of a nonmedicated solution. Observation and scoring on all days were conducted to specifically include neurologic signs typical of ivermectin toxicosis, including lethargy, ataxia, abnormal mydriasis, and abnormal salivation.
  
  
  RESULTS
  None of the dogs had clinical abnormalities during the study period.
  
  
  CONCLUSIONS
  Analysis of results of this study indicates that dermal application of 10.0% imidacloprid-0.08% ivermectin is safe for use in ivermectin-sensitive Collies at dose rates of 3 or 5 times the proposed maximum therapeutic dose.
authors.affiliation: Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802, USA.
authors.forename: Allan J
authors.initials: AJ
authors.lastname: Paul
authors.forename: Douglas E
authors.initials: DE
authors.lastname: Hutchens
authors.forename: Lawrence D
authors.initials: LD
authors.lastname: Firkins
authors.forename: Coleen M
authors.initials: CM
authors.lastname: Keehan
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D000977:Antiparasitic Agents / Q000009:adverse effects*; D004283:Dog Diseases / Q000139:chemically induced*; D004285:Dogs / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004342:Drug Hypersensitivity / Q000662:veterinary*; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007559:Ivermectin / Q000008:administration & dosage / Q000009:adverse effects*; D000073943:Neonicotinoids; D009574:Nitro Compounds
chemical_list: D000977:Antiparasitic Agents; D007093:Imidazoles; D000073943:Neonicotinoids; D009574:Nitro Compounds; C082359:imidacloprid; D007559:Ivermectin